Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608543 | 0.81 | SMN1; SMN2 (0.39) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL5608576 | 0.77 | GAA (0.36) | EPHX1HPGDNPSR1 | |
| SCHEMBL5608908 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MAPTTSHRATMHPGD | |
| SCHEMBL5608730 | 0.76 | EPHX1 (0.39) | CA12CA1CA2CA9EPHX1 | |
| SCHEMBL5608930 | 0.75 | PPM1B (0.45) | ALDH1A1MAPTHPGD | |
| SCHEMBL1170184 | 0.72 | TSHR (0.39) | TSHRCA12CA1CA2MMP2 | |
| SCHEMBL1421696 | 0.72 | SMN1; SMN2 (0.44) | ALDH1A1TSHREPHX1 | |
| SCHEMBL10260369 | 0.72 | SMN1; SMN2 (0.44) | ALDH1A1TSHREPHX1 | |
| SCHEMBL10260332 | 0.72 | SMN1; SMN2 (0.44) | ALDH1A1TSHREPHX1 | |
| SCHEMBL5194126 | 0.72 | SUCNR1 (0.42) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | ALDH1A1 349/4885MAPT 4136/4885AHCY 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.